Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) shares gapped down prior to trading on Friday. The stock had previously closed at $151.02, but opened at $129.00. Belite Bio shares last traded at $128.7930, with a volume of 194,973 shares changing hands.
Analysts Set New Price Targets
A number of research firms recently weighed in on BLTE. Mizuho raised their target price on shares of Belite Bio from $221.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday. Canaccord Genuity Group raised their target price on shares of Belite Bio from $303.00 to $314.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright restated a “buy” rating and set a $245.00 target price on shares of Belite Bio in a research note on Thursday, October 15th. UBS Group reissued a “buy” rating on shares of Belite Bio in a report on Thursday, September 3rd. Finally, Cantor Fitzgerald lifted their price target on shares of Belite Bio from $266.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $226.91.
View Our Latest Analysis on Belite Bio
Belite Bio Price Performance
The firm has a market capitalization of $5.25 billion, a price-to-earnings ratio of -47.82 and a beta of -1.19. The business’s fifty day simple moving average is $158.54 and its 200 day simple moving average is $159.99.
Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19. Equities research analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.06 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Hao-Yuan Chuang sold 49,433 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $187.64, for a total value of $9,275,608.12. Following the completion of the sale, the chief financial officer owned 44,000 shares in the company, valued at $8,256,160. This represents a 52.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Hendrik Scholl sold 2,000 shares of the stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $165.99, for a total transaction of $331,980.00. Following the completion of the sale, the insider owned 12,500 shares of the company’s stock, valued at approximately $2,074,875. This trade represents a 13.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 170,330 shares of company stock valued at $32,301,098 in the last three months. 13.29% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Belite Bio
Several large investors have recently modified their holdings of BLTE. Marshall Wace LLP bought a new stake in shares of Belite Bio in the third quarter valued at approximately $15,282,000. Great Point Partners LLC purchased a new position in shares of Belite Bio during the third quarter worth about $12,736,000. Candriam S.C.A. bought a new position in shares of Belite Bio in the 3rd quarter worth $10,711,000. Affinity Asset Advisors LLC raised its position in Belite Bio by 225.0% during the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock valued at $10,364,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Belite Bio during the 1st quarter valued at about $8,291,000. Hedge funds and other institutional investors own 0.53% of the company’s stock.
About Belite Bio
Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.
Further Reading
- Five stocks we like better than Belite Bio
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
- Apple’s Rare Samsung Memory Plan Could Solve One Problem and Create Another
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
